Retinitis Pigmentosa (Retinitis)-Pipeline Review, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline Review, H2 2017


  • Products Id :- GMDHC10033IDB
  • |
  • Pages: 164
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Retinitis Pigmentosa (Retinitis)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis)-Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 3, 1, 25 and 9 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 10 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinitis Pigmentosa (Retinitis)-Overview

Retinitis Pigmentosa (Retinitis)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Retinitis Pigmentosa (Retinitis)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinitis Pigmentosa (Retinitis)-Companies Involved in Therapeutics Development

2-BBB Medicines BV

Acucela Inc

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

Applied Genetic Technologies Corp

Astellas Pharma Inc

Caladrius Biosciences Inc

Dompe Farmaceutici SpA

Eyevensys SAS

GenSight Biologics SA

Grupo Ferrer Internacional SA

ID Pharma Co Ltd

InFlectis BioScience

Ionis Pharmaceuticals Inc

M's Science Corp

MimeTech Srl

Mimetogen Pharmaceuticals Inc

Nanovector srl

Novartis AG

Novelion Therapeutics Inc

ProQR Therapeutics NV

Recursion Pharmaceuticals Inc

ReNeuron Group Plc

SanBio Inc

Sanofi

Spark Therapeutics Inc

Sun Pharma Advanced Research Company Ltd 40

Retinitis Pigmentosa (Retinitis)-Drug Profiles

A-004-Drug Profile

AGTC-501-Drug Profile

AMRS-001-Drug Profile

Antibodies to Antagonize IL-6 for Retinitis-Drug Profile

Antisense Oligonucleotides to Activate Usherin for Retinitis Pigmentosa-Drug Profile

AP-1-Drug Profile

cenegermin-Drug Profile

CPK-850-Drug Profile 60

cutamesine-Drug Profile

EYS-611-Drug Profile

FAB-111-Drug Profile

Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa-Drug Profile

Gene Therapy for Glaucoma and Retinitis Pigmentosa-Drug Profile

Gene Therapy for Ocular Diseases-Drug Profile

Gene Therapy for Retinitis Pigmentosa-Drug Profile

Gene Therapy for Retinitis Pigmentosa-Drug Profile

Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa-Drug Profile 70

Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa-Drug Profile

Gene Therapy to Activate MERTK for Retinitis Pigmentosa-Drug Profile

Gene Therapy to Activate mVChR1 for Retinits Pigmentosa-Drug Profile

Gene Therapy to Activate RdCVF for Retinitis Pigmentosa-Drug Profile

Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa-Drug Profile

Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa-Drug Profile

GS-030-Drug Profile

HORAPDE-6B-Drug Profile 80

HORARLBP-1-Drug Profile

HORARPE-65-Drug Profile

IFB-088-Drug Profile

IONISRHO-2.5Rx-Drug Profile

KIRA-6-Drug Profile

KUS-121-Drug Profile

KUS-187-Drug Profile

LPDF-003-Drug Profile

MT-8-Drug Profile

myriocin-Drug Profile 90

N-acetyl cysteine amide-Drug Profile

NPI-001-Drug Profile

NT-501-Drug Profile

OCU-100-Drug Profile

QRX-411-Drug Profile

QRX-421-Drug Profile

ReN-003-Drug Profile

RST-001-Drug Profile

SAR-421869-Drug Profile

SB-623-Drug Profile

Small Molecule for Retinitis Pigmentosa-Drug Profile

Small Molecules 1 for Retinitis Pigmentosa-Drug Profile

Small Molecules 2 for Retinitis Pigmentosa-Drug Profile

Small Molecules 3 for Retinitis Pigmentosa-Drug Profile

Small Molecules 4 for Retinitis Pigmentosa-Drug Profile

Small Molecules for Retinitis Pigmentosa-Drug Profile

Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa-Drug Profile

Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis-Drug Profile

STC-1-Drug Profile

Stem Cell Therapy for AMD and Retinitis Pigmentosa-Drug Profile

Stem Cell Therapy for Ophthalmic Disorders-Drug Profile

Stem Cell Therapy for Retinitis Pigmentosa-Drug Profile

Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration-Drug Profile

Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa-Drug Profile

voretigene neparvovec-Drug Profile

zuretinol acetate-Drug Profile

Retinitis Pigmentosa (Retinitis)-Dormant Projects

Retinitis Pigmentosa (Retinitis)-Discontinued Products

Retinitis Pigmentosa (Retinitis)-Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 160

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by 2-BBB Medicines BV, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Acucela Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Allergan Plc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Amgen Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Applied Genetic Technologies Corp, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Astellas Pharma Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Caladrius Biosciences Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Dompe Farmaceutici SpA, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Eyevensys SAS, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by GenSight Biologics SA, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Grupo Ferrer Internacional SA, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by ID Pharma Co Ltd, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by InFlectis BioScience, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by M's Science Corp, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by MimeTech Srl, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Mimetogen Pharmaceuticals Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Nanovector srl, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Novartis AG, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Novelion Therapeutics Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by ProQR Therapeutics NV, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Recursion Pharmaceuticals Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by ReNeuron Group Plc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by SanBio Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Sanofi, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Spark Therapeutics Inc, H2 2017

Retinitis Pigmentosa (Retinitis)-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Retinitis Pigmentosa (Retinitis)-Dormant Projects, H2 2017

Retinitis Pigmentosa (Retinitis)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Retinitis Pigmentosa (Retinitis)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

2-BBB Medicines BV

Acucela Inc

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

Applied Genetic Technologies Corp

Astellas Pharma Inc

Caladrius Biosciences Inc

Dompe Farmaceutici SpA

Eyevensys SAS

GenSight Biologics SA

Grupo Ferrer Internacional SA

ID Pharma Co Ltd

InFlectis BioScience

Ionis Pharmaceuticals Inc

M's Science Corp

MimeTech Srl

Mimetogen Pharmaceuticals Inc

Nanovector srl

Novartis AG

Novelion Therapeutics Inc

ProQR Therapeutics NV

Recursion Pharmaceuticals Inc

ReNeuron Group Plc

SanBio Inc

Sanofi

Spark Therapeutics Inc

Sun Pharma Advanced Research Company Ltd

select a license
Single User License
USD 2000 INR 137800
Site License
USD 4000 INR 275600
Corporate User License
USD 6000 INR 413400

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com